CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Andrew Schwab sold 32,018 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director owned 2,433,280 shares of the company’s stock, valued at approximately $10,949,760. This trade represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
CAMP4 Therapeutics Price Performance
CAMP opened at $4.48 on Friday. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.41 and a fifty-two week high of $7.75. The firm has a market capitalization of $281.12 million, a price-to-earnings ratio of -1.93 and a beta of 0.22. The company’s 50 day moving average price is $4.12 and its two-hundred day moving average price is $4.34.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, equities research analysts predict that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.
Institutional Trading of CAMP4 Therapeutics
Analyst Upgrades and Downgrades
Several research analysts have commented on CAMP shares. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research report on Friday, August 14th. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Finally, Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.56.
Check Out Our Latest Report on CAMP
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Read More
- Five stocks we like better than CAMP4 Therapeutics
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
